"ERG1 Potassium Channel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of three members of the ether-a-go-go (EAG) POTASSIUM CHANNELS gene family comprising ether-a-go-go (eag), eag-like (elk) and eag-related (erg) subfamilies. Ether-a-go-go-related gene 1 (ERG1) also known as KCNH2, encodes the pore-forming subunit of a rapidly activating-delayed rectifier potassium channel that plays an essential role in the final repolarization of ventricular action potential. Loss-of-function mutations in human hERG1 is associated with life-threatening ARRHYTHMIA.
| Descriptor ID |
D000072237
|
| MeSH Number(s) |
D12.776.157.530.400.600.900.249.500 D12.776.543.550.450.750.900.249.500 D12.776.543.585.400.750.900.249.500
|
| Concept/Terms |
ERG1 Potassium Channel- ERG1 Potassium Channel
- Channel, ERG1 Potassium
- Potassium Channel, ERG1
- Potassium Voltage-Gated Channel, Subfamily H, Member 2
- Ether-A-Go-Go-Related Potassium Channel 1
- Ether A Go Go Related Potassium Channel 1
Kv11.1 Protein-Potassium Channel- Kv11.1 Protein-Potassium Channel
- Channel, Kv11.1 Protein-Potassium
- Kv11.1 Protein Potassium Channel
- Protein-Potassium Channel, Kv11.1
|
Below are MeSH descriptors whose meaning is more general than "ERG1 Potassium Channel".
Below are MeSH descriptors whose meaning is more specific than "ERG1 Potassium Channel".
This graph shows the total number of publications written about "ERG1 Potassium Channel" by people in this website by year, and whether "ERG1 Potassium Channel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "ERG1 Potassium Channel" by people in Profiles.
-
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels. J Pharmacol Exp Ther. 2021 05; 377(2):265-272.
-
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. Eur J Pharmacol. 2021 Feb 15; 893:173813.
-
Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression. Cardiovasc Res. 2019 Aug 01; 115(10):1500-1511.
-
Postmortem Analysis of 4 Mutation Hotspots of KCNQ1, KCNH2, and SCN5A Genes in Sudden Unexplained Death in Southwest of China. Am J Forensic Med Pathol. 2018 Sep; 39(3):218-222.
-
Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J. 2018 04 21; 39(16):1446-1455.
-
Application of Multigene Panel Sequencing in Patients with Prolonged Rate-corrected QT Interval and No Pathogenic Variants Detected in KCNQ1, KCNH2, and SCN5A. Ann Lab Med. 2018 Jan; 38(1):54-58.
-
Hypoxia reduces mature hERG channels through calpain up-regulation. FASEB J. 2017 11; 31(11):5068-5077.
-
The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. Int J Cardiol. 2017 Aug 01; 240:367-371.
-
Characterization and structure-activity relationship of natural flavonoids as hERG K+ channel modulators. Int Immunopharmacol. 2017 Apr; 45:187-193.